TrimMedium
In Stage 4 decline, MAZE retains a medium-term bearish bias driven by recent Support Failure and Bearish Pivot Point patterns, with price trading below declining EMAs. Price now rests at a multi-touch support zone, making short-term timing unclear. Selling into resistance around the 9- and 20-day EMAs on a failed bounce is preferred over immediate execution.
- ↑36% mean UACR reduction in Horizon Trial exceeds 30% threshold
- ↑MZE829 targets ~6 million US AMKD patients lacking approved therapy
- ↓Q2 2026 EPS of –$0.76 missed the –$0.70 estimate, underscoring losses
Full analysis →